GlassScriptPhysician profile
Maria Serrano
NPI 1013097666
$7,666.35
in general payments reported to CMS, 2019-2025
34 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $1,969 · 2023: $1,757 · 2024: $1,592 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,716.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $740.08 | 2022-2024 | Reblozyl, Opdivo |
| Janssen Biotech, INC. | $676.04 | 2021-2024 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $647.58 | 2021-2025 | Imfinzi, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $517.36 | 2021-2023 | Imbruvica |
| Daiichi Sankyo INC. | $498.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $432.79 | 2023-2025 | Keytruda, Keytruda Qlex |
| Exelixis INC. | $372.20 | 2023-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $337.57 | 2023-2024 | Libtayo |
| Seagen INC. | $303.46 | 2021-2022 | |
| Abbvie INC. | $301.45 | 2024-2025 | |
| Puma Biotechnology, INC. | $250.00 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $243.88 | 2022-2023 | Xpovio |
| Jazz Pharmaceuticals INC. | $194.60 | 2024 | |
| Immunocore Limited | $132.49 | 2025 | Kimmtrak |
| Amgen INC. | $130.95 | 2025 | Imdelltra (Amg757) |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $129.55 | 2025 | Optune Lua (Novottf-200t) |
| Legend Biotech USA INC. | $128.32 | 2025 | Carvykti |
| Coherus Oncology, INC. | $125.21 | 2021 | |
| Celgene Corporation | $125.00 | 2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2025 | Jemperli |
| Taiho Oncology, INC. | $125.00 | 2022 | |
| Eisai INC. | $122.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.07 | 2022 | |
| Springworks Therapeutics, INC. | $121.84 | 2025 | Ogsiveo |
| Genzyme Corporation | $118.89 | 2021 | |
| Genmab U.S., INC. | $115.74 | 2024 | Tivdak |
| Kite Pharma, INC. | $94.38 | 2024 | |
| Boston Scientific Corporation | $92.24 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $91.78 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $82.77 | 2023 | Rybrevant |
| Lilly USA, LLC | $69.33 | 2024-2025 | Verzenio |
| Otsuka America Pharmaceutical, INC. | $46.55 | 2024 | Rexulti |
| Deciphera Pharmaceuticals INC. | $27.68 | 2025 | Romvimza, Qinlock |
| Intuitive Surgical, INC. | $23.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.